发布时间：2025-11-25 10:06 Cladribine capsules have the potential to be the first oral treatment for people living with rare, chronic autoimmune neuromuscular disorder, generalized Myasthenia Gravis
Cladribine capsules has received Fast Track designation and Orphan Drug Designation by the US FDA
Merck has established an MG patient council to provide insights on how to best meet the needs of patients in the gMG rare disease community
DARMSTADT, Germany -- (BUSINESS WIRE) --

Merck, a leading science and technology company, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for cladribine capsules for the treatment of the rare, chronic autoimmune neuromuscular disorder, generalized Myasthenia Gravis (gMG). In June 2023, the FDA granted Orphan Drug Designation for cladribine capsules for the treatment of gMG. In addition, the Company is actively collaborating with patient organizations and Ad Scientiam, a medical technology company
=*=*=*=*=*=
当前为第1/8页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页